Biotest AG
XETRA:BIO

Watchlist Manager
Biotest AG Logo
Biotest AG
XETRA:BIO
Watchlist
Price: 41.4 EUR
Market Cap: 1.6B EUR
Have any thoughts about
Biotest AG?
Write Note

Gross Margin
Biotest AG

34%
Current
27%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
34%
=
Gross Profit
240m
/
Revenue
707m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
DE
Biotest AG
XETRA:BIO
1.6B EUR
34%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
315.2B USD
67%
US
Amgen Inc
NASDAQ:AMGN
141.9B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
135.7B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
36B EUR
89%
Country DE
Market Cap 1.6B EUR
Gross Margin
34%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 315.2B USD
Gross Margin
67%
Country US
Market Cap 141.9B USD
Gross Margin
60%
Country US
Market Cap 116.4B USD
Gross Margin
78%
Country US
Market Cap 104.5B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.7B AUD
Gross Margin
52%
Country US
Market Cap 78.7B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

Biotest AG
Glance View

Market Cap
1.6B EUR
Industry
Biotechnology

Biotest AG, headquartered in Dreieich, Germany, is a pivotal player in the field of biopharmaceuticals, with a particular focus on blood plasma-derived products. The company traces its origins back to 1946 when it was founded as a laboratory for blood testing, and since then, it has transformed into a significant force in the healthcare sector. Biotest operates on a vertically integrated business model, from collecting plasma to the manufacturing and distribution of therapeutic proteins. The company primarily produces and markets products like immunoglobulins, coagulation factors, and albumins, which are essential for treating immune system deficiencies, blood clotting disorders, and various other ailments. These products serve not only to improve the quality of life for patients but are critical lifelines for those with chronic and acute conditions. Revenue generation at Biotest revolves around a three-pronged strategy: plasma collection, manufacturing, and commercialization of its proprietary therapies. The process begins with the acquisition of raw plasma through an extensive network of collection centers. This plasma is then processed and transformed into high-value therapeutic products in sophisticated manufacturing facilities. Biotest’s revenue stream is bolstered by its strong presence in international markets, serving hospitals, clinics, and healthcare systems with high demand for its specialized products. By leveraging its in-depth expertise in plasma technology and robust infrastructure, Biotest AG has carved a niche, ensuring a steady flow of returns while contributing significantly to advancements in treating rare diseases and fostering global health betterment.

BIO Intrinsic Value
32.17 EUR
Overvaluation 22%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
34%
=
Gross Profit
240m
/
Revenue
707m
What is the Gross Margin of Biotest AG?

Based on Biotest AG's most recent financial statements, the company has Gross Margin of 34%.